



The **EmERGE** project
Evaluating **mHealth**
technology in HIV to
improve **Empowerment**
and healthcare utilisation:
Research and innovation
to **G**enerate **E**vidence for
personalised care.

Web

www.emergeproject.eu



Project leader and partners

- **BRIGHTON AND SUSSEX UNIVERSITY HOSPITALS NHS TRUST (BSUHT)** - UK
- **UNIVERSITY OF SUSSEX (UOS)** - UK
- **EUROPEAN AIDS TREATMENT GROUP (EATG)** - Belgium
- **UNIVERSITY OF BRIGHTON (UOB)** - UK
- **PRINS LEOPOLD INSTITUUT VOOR TROPISCHE GENEESKUNDE (ITM)** - Belgium
- **FUNDACIO PRIVADA CLINIC PER A LA RECERCA BIOMEDICA (FCRB)** - Spain
- **CENTRO HOSPITALAR DE LISBOA CENTRAL, EPE (CHLC)** - Portugal
- **KLINIKA ZA INFektivNE BOLESTI DR. FRAN MIHALJEVIC (KIB)** - Croatia
- **NPMS-HHC CIC (NPMS)** - UK
- **UNIVERSIDAD POLITECNICA DE MADRID (UPM)** - Spain
- **EmERGE mHealth Ltd (EmH)** - UK
- **MODUS RESEARCH AND INNOVATION (MODUS)** - UK



EmERGE is a project funded by the European Union's Horizon 2020 Research and Innovation Programme under Grant agreement no: 643736.

For more information please contact the European AIDS Treatment Group
Email: projects@eatg.org



EmERGE

mHealth technology in HIV
to improve empowerment
and healthcare utilisation

Project description

EmERGE is a project funded by the European Union's Horizon 2020 Research and Innovation Programme under Grant agreement no: 643736.

EmERGE has developed mHealth platforms to enable self-management of people living with stable HIV. The platforms are built upon and integrate the existing mHealth solutions operated by pioneering healthcare providers in the UK and Spain and apply a rigorous co-design approach to ensure patient and clinician input to the solution.



EmERGE
providers effectiveness
care cost
management self
assessment health
mHealth PLHIV monitoring remote

Objectives

The platforms will provide web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to key healthcare providers. EATG, as community partner, provides a direct and deep interaction with patient and clinician representatives from five EU countries.

Validation

The platforms and interfaces will be validated in a large study of over 2,200 patients using a tailored Health Technology Assessment (HTA) process, specifically developed for the assessment of mHealth solutions including translatability as a key factor.

Expected outcomes and deliverables

Innovation will be given priority by developing new business models of care provision, targeting key stakeholders in the EU health sector, including policy makers and clinicians, while eliciting demand from patients to initiate the widespread implementation of mHealth solutions within the timeframe of the project.

Policy briefs will be produced to provide evidence of the benefits and share the lessons learned to support the uptake of mHealth for self-management of other chronic conditions.

Workpackages

EmERGE has 9 workpackages (WP):

- **WP1** Situational analysis and background assessment. WP leader: ITM
- **WP2** Sociotechnical evaluation. WP leader: UOB
- **WP3** Health Economics. WP leader: NPMS
- **WP4** Platform development and deployment. WP leader: UPM
- **WP5** Study co-ordination and Management. WP leader: FCRB
- **WP6** Quantitative patient outcomes. WP leader: BSUHT
- **WP7** Innovation and Exploitation. WP leader: UOB
- **WP8** Dissemination and Popularisation. WP leader: EATG
- **WP9** Project Management: WP leader: MODUS

Validation

EmERGE aims to demonstrate the benefits to patients and simultaneous increases in cost- effectiveness for health-care providers and purchasers by reducing face-to-face consultations based on prior work showing a high uptake rate and use of mHealth in HIV patient populations.

“Creating mHealth solutions to facilitate remote access to health care providers for People Living with HIV (PLHIV).”

